New research indicates that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who stop conventional lifestyle programs.
Research printed in a leading health publication points out that while obese individuals can lose about a fifth of their total mass while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Users using such medications must be cognizant of the risk of fast rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment mass in about one and a half years.
Weighing Therapies
The analysis, which reviewed dozens of studies involving over 9,000 of participants, compared the results of these new drugs with other pills.
Researchers point out that individuals who shed pounds through diet and exercise typically experience a slower weight regain—around 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Doctors suggest the mode of action of the drugs is key to understanding the accelerated weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating far more likely."
A Lifelong Disease?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, given the likelihood of weight regain, the therapy should be considered life-long.
This opinion is supported by drug manufacturers, who state that the findings "underscore the persistent nature of excess weight," comparing it to managing conditions like diabetes.
User Testimonies
People who have discontinued the jabs report a sudden return of cravings.
"It was like something that goes on and I was suddenly starving," said one woman.
This difficulty is worsened if users have not adopted sustainable dietary or behavioural modifications during treatment.
Widespread Interest
Figures indicate that millions of adults in the UK have tried these injections in the past year, with demand being substantial.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
Finally, researchers stress that while the jabs are effective agents for weight loss, they are not a standalone cure and maintained weight loss likely depends on integrated behavioural management.
